Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

US11679075B2 · kind B2 · utility

Assignee

• BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · US

Inventors

• Irving H. Zucker · Omaha, US
• Hanjun Wang · Omaha, US

Key dates

• Filing date: Jun 24, 2020
• Grant date: Jun 20, 2023
• Expiry date: Mar 25, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/357
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.